Moderna Starts Phase 3 Clinical Trial of Its Coronavirus Vaccine Candidate
One of the most eagerly anticipated clinical trials of our time has begun. Moderna (NASDAQ: MRNA) announced Monday that it has started inoculating patients in the phase 3 study of mRNA-1273, its coronavirus vaccine candidate.
The large-scale study will involve around 30,000 participants throughout the U.S., and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).
Moderna, a young biotech, was selected to receive extra support from the U.S. government's Operation Warp Speed program, which has the goal of speeding up the development of promising vaccines and treatments for COVID-19. The COVE (coronavirus efficacy) study is placebo-controlled and randomized, and has as its primary endpoint the prevention of symptomatic cases of COVID-19. There are a number of secondary endpoints, most notably the prevention of coronavirus infection entirely.
Source Fool.com